Overview and Scope
The cervical cancer vaccine refers to a vaccine that is specifically developed to prevent the occurrence of cervical cancer by targeting the high-risk types of human papillomavirus (HPV) that are responsible for most cases of cervical cancer. The vaccines stimulate an immune response in the body, producing antibodies that can recognize and neutralize the HPV virus.
Sizing and Forecast
The cervical cancer vaccine market size has grown strongly in recent years. It will grow from $82.74 billion in 2023 to $88.39 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to awareness campaigns and education, government initiatives and vaccination programs, increased incidence of cervical cancer, healthcare provider recommendations, global efforts for women’s health..
The cervical cancer vaccine market size is expected to see strong growth in the next few years. It will grow to $117.01 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to expansion of vaccination coverage, integration into routine immunization programs, advancements in hpv testing and screening, global advocacy for hpv vaccination, rising focus on adolescent vaccination.. Major trends in the forecast period include incorporation of new adjuvants, integration of digital health platforms, innovative vaccine development, public-private partnerships, educational campaigns and advocacy..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/cervical-cancer-vaccine-global-market-report
Segmentation & Regional Insights
The cervical cancer vaccine market covered in this report is segmented –
1) By Type: Cervarix, Gardasil, Gardasil 9
2) By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-Users: Hospital, Biotechnology Company, Academic And Research Organizations, Other End-Users
North America was the largest region in the cervical cancer vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cervical cancer vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=11886&type=smp
Major Driver Impacting Market Growth
The rising prevalence of cervical cancer cases is expected to propel the growth of the cervical cancer vaccine market going forward. Cervical cancer refers to a type of cancer that affects the lower part of the uterus (womb), the cervix, which connects to the upper part of the vagina. The rising number of cervical cancer cases is mostly driven by a lack of Human papillomavirus vaccines (HPV) vaccination, a lack of hygiene, and insufficient awareness and knowledge about cervical cancer. Cervical cancer vaccines are highly effective in preventing the development of cervical cancer by targeting the high-risk types of human papillomavirus (HPV). For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cervical cancer cases reported in the US was 13,960. Therefore, the rising number of cervical cancer cases is driving the growth of the cervical cancer vaccine market.
Key Industry Players
Major companies operating in the cervical cancer vaccine market report are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., Novartis AG, Sanofi Pasteur, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Serum Institute of India (SII), Walvax Biotechnology Co Limited, Bavarian Nordic A/S, CureVac N.V, Profectus Biosciences Inc., Genexine Inc., Inovio Pharmaceuticals Inc., Aston Scientific Inc., Ultimovacs ASA, Nykode Therapeutics AS, Heat Biologics Inc., Northwest Biotherapeutics Inc., VBI Vaccines Inc., OncBioMune Pharmaceuticals Inc., Advaxis Inc., Immunovaccine Inc.
The cervical cancer vaccine market report table of contents includes:
1. Executive Summary
2. Cervical Cancer Vaccine Market Characteristics
3. Cervical Cancer Vaccine Market Trends And Strategies
4. Cervical Cancer Vaccine Market – Macro Economic Scenario
5. Global Cervical Cancer Vaccine Market Size and Growth
.
.
.
31. Cervical Cancer Vaccine Market Other Major And Innovative Companies
32. Global Cervical Cancer Vaccine Market Competitive Benchmarking
33. Global Cervical Cancer Vaccine Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Cervical Cancer Vaccine Market
35. Cervical Cancer Vaccine Market Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
